These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15950442)

  • 21. Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia.
    Miller DD; Andreasen NC; O'Leary DS; Watkins GL; Boles Ponto LL; Hichwa RD
    Biol Psychiatry; 2001 Apr; 49(8):704-15. PubMed ID: 11313038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with haloperidol and diazepam alters GABA(A) receptor density in the rat brain.
    McLeod MC; Sundram S; Dean B
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):560-7. PubMed ID: 18045761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics.
    Sabri O; Erkwoh R; Schreckenberger M; Cremerius U; Schulz G; Dickmann C; Kaiser HJ; Steinmeyer EM; Sass H; Buell U
    J Nucl Med; 1997 Feb; 38(2):181-8. PubMed ID: 9025731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol.
    Harte MK; Bachus SB; Reynolds GP
    Schizophr Res; 2005 Jun; 75(2-3):303-8. PubMed ID: 15885521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of haloperidol dose on iodine-123-IBZM brain SPECT imaging in schizophrenic patients.
    Vallabhajosula S; Hirschowitz J; Machac J
    J Nucl Med; 1997 Feb; 38(2):203-7. PubMed ID: 9025736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation.
    Duncan GE; Miyamoto S; Lieberman JA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):999-1005. PubMed ID: 12626664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebral blood flow changes in very-late-onset schizophrenia-like psychosis with catatonia before and after successful treatment.
    Tsujino N; Nemoto T; Yamaguchi T; Katagiri N; Tohgi N; Ikeda R; Shiraga N; Mizumura S; Mizuno M
    Psychiatry Clin Neurosci; 2011 Oct; 65(6):600-3. PubMed ID: 22003993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.
    Battaglia J; Houston JP; Ahl J; Meyers AL; Kaiser CJ
    Clin Ther; 2005 Oct; 27(10):1612-8. PubMed ID: 16330297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olanzapine and haloperidol for residual symptoms.
    de Haan L; van Beveren N
    Am J Psychiatry; 2005 Jul; 162(7):1392-3; author reply 1393. PubMed ID: 15994737
    [No Abstract]   [Full Text] [Related]  

  • 30. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
    Wright P; Birkett M; David SR; Meehan K; Ferchland I; Alaka KJ; Saunders JC; Krueger J; Bradley P; San L; Bernardo M; Reinstein M; Breier A
    Am J Psychiatry; 2001 Jul; 158(7):1149-51. PubMed ID: 11431240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroleptic therapy influences basal ganglia activation: a functional magnetic resonance imaging study comparing controls to haloperidol- and olanzapine-treated inpatients.
    Müller JL; Klein HE
    Psychiatry Clin Neurosci; 2000 Dec; 54(6):653-8. PubMed ID: 11145463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study.
    Abler B; Erk S; Walter H
    Psychopharmacology (Berl); 2007 Apr; 191(3):823-33. PubMed ID: 17265148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
    Kahn RS; Fleischhacker WW; Boter H; Davidson M; Vergouwe Y; Keet IP; Gheorghe MD; Rybakowski JK; Galderisi S; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Grobbee DE;
    Lancet; 2008 Mar; 371(9618):1085-97. PubMed ID: 18374841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
    Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
    Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia.
    Buchsbaum MS; Haznedar M; Newmark RE; Chu KW; Dusi N; Entis JJ; Goldstein KE; Goodman CR; Gupta A; Hazlett E; Iannuzzi J; Torosjan Y; Zhang J; Wolkin A
    Schizophr Res; 2009 Oct; 114(1-3):161-71. PubMed ID: 19695836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug.
    Glenthoj A; Glenthoj BY; Mackeprang T; Pagsberg AK; Hemmingsen RP; Jernigan TL; Baaré WF
    Psychiatry Res; 2007 Apr; 154(3):199-208. PubMed ID: 17360162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically.
    Holcomb HH; Lahti AC; Medoff DR; Weiler M; Tamminga CA
    Neuropsychopharmacology; 2001 Aug; 25(2):165-72. PubMed ID: 11425500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration.
    Morrens M; Wezenberg E; Verkes RJ; Hulstijn W; Ruigt GS; Sabbe BG
    J Clin Psychopharmacol; 2007 Feb; 27(1):15-21. PubMed ID: 17224707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration.
    Guma E; Rocchetti J; Devenyi GA; Tanti A; Mathieu AP; Lerch JP; Elgbeili G; Courcot B; Mechawar N; Chakravarty MM; Giros B
    Sci Rep; 2019 May; 9(1):7850. PubMed ID: 31127135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.